A REGISTRY TO COLLECT CHARACTERISTICS AND OUTCOMES FROM PATIENTS WITH SOLID TUMORS PROFILED WITH A NEXT-GENERATION SEQUENCING TEST (WAYFIND-R)

A REGISTRY TO COLLECT CHARACTERISTICS AND OUTCOMES FROM PATIENTS WITH SOLID TUMORS PROFILED WITH A NEXT-GENERATION SEQUENCING TEST (WAYFIND-R) - WAYFIND-R

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

LBCTR

Registry ID

LBCTR2022105085

Enrollment

15000

Registered

2025-08-14

Start date

2022-11-15

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The registry population will include adult patients who are diagnosed with solid tumor cancers (at any anatomical location) and at any stage of the disease. ALL SOLID TUMORS

Interventions

Non-interventional study

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients must meet the following criteria for enrolment in this registry: - Patient is an adult (according to age of majority as defined by local regulations) - Patient is currently diagnosed with any type of solid tumor cancer, at any stage of the disease, at the enrolment date (informed consent date) - Patient has undergone NGS testing, no longer than 3 months prior to the enrolment date, irrespective of the availability of test results - Informed consent has been obtained from the patient or legally authorized representative, as per local regulations

Exclusion criteria

Exclusion criteria: Patients who meet the below exclusion criterion at the time of enrolment will not be enrolled in this registry: - Patient has a prior or current diagnosis of hematological malignancy

Design outcomes

Primary

Measure	Time frame
Name: To provide a platform to support the design and conduct of clinical and epidemiological research ;Timepoints: NA being that it's a registry;Measure: - Collect data that can inform future trial design and facilitate identification of potential trial populations - Provide a resource to identify, develop and qualify biomarkers, novel assessment tools and clinical endpoints - Provide a resource to support the conduct of disease-modeling studies ;Name: To develop an evidence-generation platform to better understand health outcomes and cancer care processes ;Timepoints: NA being that it's a registry;Measure: - Provide a resource to inform how precision medicine tools are used and how they affect patient care in the real world - Provide a resource to generate evidence that can support clinical, regulatory and access decision-making - Provide a resource to identify and assess clinical practices that can improve the healthcare of affected individuals ;Name: To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing ;Timepoints: NA being that it's a registry;Measure: - Collect data that describes the history of patients undergoing NGS testing - Collect data that can help identify the complex genomic landscape affecting the diagnosis and prognosis of solid tumor cancers and deepen the understanding of underlying biologic pathways - Collect data that can help identify sub-populations that may best benefit from precision medicine tools	—

Measure

Time frame

Name: To provide a platform to support the design and conduct of clinical and epidemiological research ;Timepoints: NA being that it's a registry;Measure: - Collect data that can inform future trial design and facilitate identification of potential trial populations - Provide a resource to identify, develop and qualify biomarkers, novel assessment tools and clinical endpoints - Provide a resource to support the conduct of disease-modeling studies ;Name: To develop an evidence-generation platform to better understand health outcomes and cancer care processes ;Timepoints: NA being that it's a registry;Measure: - Provide a resource to inform how precision medicine tools are used and how they affect patient care in the real world - Provide a resource to generate evidence that can support clinical, regulatory and access decision-making - Provide a resource to identify and assess clinical practices that can improve the healthcare of affected individuals ;Name: To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing ;Timepoints: NA being that it's a registry;Measure: - Collect data that describes the history of patients undergoing NGS testing - Collect data that can help identify the complex genomic landscape affecting the diagnosis and prognosis of solid tumor cancers and deepen the understanding of underlying biologic pathways - Collect data that can help identify sub-populations that may best benefit from precision medicine tools

—

Secondary

Measure	Time frame
Name: NA - It's a registry;Timepoints: NA;Measure: NA	—

Countries

Argentina, Austria, Brazil, Canada, Chile, Colombia, Egypt, Estonia, France, Germany, Greece, Hungary, India, Ireland, Lebanon, Mexico, Philippines, Poland, Portugal, Republic of Serbia, Saudi Arabia, Slovakia, Slovenia, South Africa, Spain, Taiwan, Thailand, Turkey, United Arab Emirates, United Kingdom, Viet Nam

Contacts

Public ContactHampig Kourie

Hotel Dieu De France

hampig.kourie@hotmail.com01604000

Outcome results

None listed

Source: LBCTR (via WHO ICTRP) · Data processed: Feb 7, 2026